electroCore, Inc (ECOR) Fair Value & Analysis
Healthcare · US · Market cap $69.9M
electroCore, Inc
ECOR · US
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price −16.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $4.31 – $10.35 · fair‑value band $10.14 – $16.89 · the $8.12 price screens below the $13.51 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
electroCore, Inc (ECOR) currently trades at $8.12, while our model-based Fair Value estimate is $13.51 — implying the stock looks roughly 66.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, electroCore, Inc generated revenue of $34.9M at a net margin of -44.1%. Revenue grew 42.6% year over year. Net debt stands at $2.4M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporat…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
electroCore, Inc reported revenue of $32.0M in FY2025 versus $5.5M in FY2021, a compound +55.7%/yr. Reported net income was −$14.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is electroCore, Inc (ECOR) undervalued?
What is the fair value of ECOR?
What is the quality score of ECOR?
What is the revenue of electroCore, Inc (ECOR)?
What is the net profit margin of ECOR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.